ArticleEsophagus : official journal of the Japan Esophageal Society2022
Clinical outcomes of surgical resection for recurrent lesion after curative esophagectomy for esophageal squamous cell carcinoma: a nationwide, large-scale retrospective study.
Article in Esophagus : official journal of the Japan Esophageal Society, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.
- Neutrophil-to-lymphocyte ratio in unresectable or metastatic esophageal squamous cell carcinoma: a systematic review, meta-analysis and meta-regression.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Pooled it
- The impact of time to postoperative recurrence on the prognosis of patients with esophageal cancer post recurrence: exploratory analysis of OGSG 1003.Esophagus : official journal of the Japan Esophageal Society · 2024Trial
- Eight-year patient survival following multidisciplinary management for two recurrences of esophageal cancer: case report and literature review.International journal of surgery case reports · 2026Article
- Survival benefit of local treatment for oligo-recurrence after esophageal cancer surgery.World journal of surgical oncology · 2026Article
- Identifying risk factors and evaluating therapeutic interventions for anastomotic recurrence in postoperative esophageal squamous cell carcinoma.BMC cancer · 2025Article
- Multimodal therapy for oligometastases after curative esophagectomy for esophageal cancer.Esophagus : official journal of the Japan Esophageal Society · 2025Article
- Outcome research on esophagectomy analyzed using nationwide databases in Japan: evidences generated from real-world data.Esophagus : official journal of the Japan Esophageal Society · 2024Review
- Use machine learning to predict pulmonary metastasis of esophageal cancer: a population-based study.Journal of cancer research and clinical oncology · 2024Article
- Predictive factors for intrathoracic anastomotic leakage and postoperative mortality after esophageal cancer resection.BMC surgery · 2024Article
- Prognostic Relevance of Recurrent Sites of Gastric Cancer Treated With Curative Resection: A Single Center Retrospective Study.Journal of gastric cancer · 2024Article
- Review
- Risk Factors of Postoperative Complication and Hospital Mortality after Colorectal Perforation Surgery.Journal of the anus, rectum and colon · 2024Article
- Esophageal cancer practice guidelines 2022 edited by the Japan Esophageal Society: part 2.Esophagus : official journal of the Japan Esophageal Society · 2023Article
- Survival after Lung Metastasectomy from Esophageal Cancer: Results from a Multi-Institutional Database.Cancers · 2023Article
- Patterns of failure after salvage chemoradiotherapy for postoperative loco-regional recurrent esophageal cancer: 20-year experience in a single institution in Japan.Esophagus : official journal of the Japan Esophageal Society · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 7 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSeveral studies have reported the efficacy of resection for recurrent lesions. However, they involved a limited number of subjects. This study aimed to identify a subset of patients who benefit from surgical resection of recurrent lesions after curative esophagectomy for esophageal squamous cell carcinoma.
methodsClinicopathological features of 186 patients with esophageal squamous cell carcinoma who underwent surgical treatment for postoperative recurrent lesions at 37 accredited institutions of the Japanese Esophageal Society were evaluated.
resultsThe most common recurrence site was the lymph node (106 cases; 58.6%), followed by the lung (40 cases; 22.1%). Univariate analyses revealed that pN 0-1 at esophagectomy (P = 0.0348), recurrence-free interval of ≥ 550 days (P = 0.0306), R0 resection (P < 0.0001), and absence of severe complications after resection for recurrent lesions (Clavien-Dindo grade < IIIa) (P = 0.0472) were associated with better overall survival after surgical resection. According to multivariate analyses, pN 0-1 (P = 0.0146), lung metastasis (P = 0.0274), recurrence-free interval after curative esophagectomy of ≥ 550 days (P = 0.0266), R0 resection (P = 0.0009), and absence of severe complications after resection for recurrent lesions (Clavien-Dindo grade < IIIa) (P = 0.0420) were independent predictive factors for better overall survival.
conclusionsSurgical resection of recurrent esophageal squamous cell carcinoma lesions is a useful option, especially for cases involving lower pN stage, lung metastasis, long recurrence-free intervals after esophagectomy, and technically resectable lesions. Surgical risks should be minimized as much as possible.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.